华法林药基因组学:设计基于DNA的电化学传感器来检测CYP2C9*2基因变异
Tiago Barbosa1,2, Stephanie L Morais2, Eduarda Pereira1,2
1REQUIMTE/LAQV, Escola Superior de Saúde, Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 400, 4200-072 Porto, Portugal.
Genes
|April 26, 2025
概括
开发了一种电化学DNA传感器来基因组化CYP2C9*2多态,帮助调整华法林剂量. 这种敏感的工具可以准确地识别患者的基因型,以实现个性化医疗.
科学领域:
- 生物医学工程 生物医学工程
- 分子诊断学 分子诊断
- 药物基因组学 药物基因组学
背景情况:
- 酶CYP2C9对于华法林代谢至关重要.
- 像CYP2C9*2一样,CYP2C9基因中的单核酸多态 (SNPs) 影响了华法林的反应.
- 精确的基因型鉴定对于优化华法林治疗至关重要.
研究的目的:
- 开发和优化一种基于DNA的电化学传感器,用于检测CYP2C9*2多态.
- 为提供精确基因定型的工具,以指导华法林剂量.
主要方法:
- 为CYP2C9*2多态变体 (A和G) 设计的DNA点探针.
- 在金电极上使用自组装单层构建了电化学传感器.
- 利用光素标记的DNA用于特定的杂交检测目标序列.
主要成果:
- 在同卵同胞的非变体 (13 pM) 和变体 (22.6 pM) 探针中达到低检测极限 (LOD).
- 演示了传感器识别互补链之间的DNA杂交的能力.
- 成功基因定型了三个具有不同CYP2C9*2基因型 (G/G,G/A,A/A) 的人类样本.
结论:
- 开发的电化学传感器可以有效地区分CYP2C9*2 SNP目标序列.
- 该传感器专门检测患者的基因型,为传统PCR提供了替代方案.
- 这项技术为基因型确定和华法林剂量预测提供了一种有前途,敏感和具有成本效益的方法.
相关概念视频
Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121


